David Liang
Cardiovascular Disease · Stanford, CANPI 1104966373
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Philips North America LLC accounts for 68.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $5,298 and has fallen 87.2% since, to $680 in 2025.
Across 35 payments — averaging $271.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$7K
- Edwards Lifesciences$2K
- Medtronic$665
- Atricure, Inc.$420
- GE HealthCare$145
- Merck$96
- plus $119 from 3 others
Across 9 payments — averaging $2194.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$10K
- Aytu Biopharma, Inc.$10K
What the payments were for
- Consulting fees$5,29856%
- Speaking & faculty fees$1,51516%
- Travel & lodging$1,06111%
- Food & beverage$1,63017%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 6 | $6,526 |
| Edwards Lifesciences | 15 | $1,532 |
| Medtronic | 2 | $665 |
| Atricure, Inc. | 4 | $420 |
| GE HealthCare | 2 | $145 |
| Merck | 1 | $96 |
| Siemens Medical Solutions USA, Inc. | 3 | $76 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Canon Medical Systems USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Other$4,798
- EPIQ 7C$1,665
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$278
- Avalus$165
How this compares
$9,503 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 149 | $206,515 |
| CamzyosMavacamten | 25 | $199,198 |
| JardianceEmpagliflozin | 40 | $55,042 |
| XareltoRivaroxaban | 25 | $37,674 |
| OzempicSemaglutide | 19 | $22,375 |
| Repatha SureclickEvolocumab | 25 | $20,425 |
| Praluent PenAlirocumab | 20 | $13,565 |
| Eplerenone | 49 | $4,818 |
| Amiodarone Hcl | 39 | $3,141 |
| Valsartan | 36 | $2,640 |
| Celecoxib | 12 | $2,531 |
| Ondansetron OdtOndansetron | 12 | $2,260 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 49 | $2,240 |
| Metoprolol Succinate | 124 | $2,162 |
| Irbesartan | 86 | $1,732 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Stanford
- Wilber SuStanford$1.1M
- Euan AshleyStanford$508K
- Kenneth MahaffeyStanford$447K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.